drugset / Trial / NCT00388999
Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant
RandomizedParallel-groupOpen-labelTreatment
Summary
MBL deficient patients enrolled in this protocol are scheduled to be treated with melphalan-based high-dose chemotherapy followed by autologous hematopoietic stem cell transplant (HSCT) for their multiple myeloma. Patients are randomized to 0.5 mg/kg, 1.0 mg/kg, or no rhMBL.
Timeline
- Start
- 2006-09
- Primary completion
- 2009-02
- Completion
- 2009-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Human Mannose-Binding Lectin | Protein / enzyme biologic | 0 mg/kg | Intravenous |
| Subject | Recombinant Human Mannose-Binding Lectin | Protein / enzyme biologic | 0.5 mg/kg | Intravenous |
| Subject | Recombinant Human Mannose-Binding Lectin | Protein / enzyme biologic | 1 mg/kg | Intravenous |